bioRxiv Science⌕ Search

bioRxiv · 10.1101/2024.06.13.598938

Antimicrobial Activity of Clove Extracts against Microorganisms Isolated from Vaginal Discharge

Abstract

Infections of the genitourinary and reproductive tracts pose significant health concerns for women, particularly those of reproductive age. These infections often manifest as vaginal discharge and can be caused by a variety of microorganisms, including pathogenic bacteria and fungi. Traditional antibiotic treatments are increasingly challenged by the rise of antibiotic-resistant strains, underscoring the need for alternative therapies. This study aimed to isolate and identify microorganisms from vaginal swab samples and evaluate the antimicrobial efficacy of clove (Eugenia caryophyllata) extracts against these isolates. Using CLED agar, nutrient agar, and Sabouraud dextrose agar, a diverse range of bacterial and fungal flora were isolated from eight vaginal swab samples. The primary bacterial isolates included Proteus mirabilis, Escherichia coli, Staphylococcus aureus, and Lactobacillus spp., while Candida albicans was the main fungal isolate. Biochemical tests confirmed the identity of these microorganisms. The study found that ethanol clove extract exhibited significant antimicrobial activity, particularly against Staphylococcus aureus and Candida albicans, with the minimum inhibitory concentration (MIC) values being 20 mg/ml and 10 mg/ml, respectively. Additionally, ciprofloxacin, used as a control antibiotic, showed maximum inhibition against Lactobacillus spp., highlighting a potential risk for disrupting beneficial vaginal flora when using conventional antibiotics. The findings suggest that ethanol clove extract could serve as an effective alternative antimicrobial agent, reducing the risk of antibiotic resistance and preserving the balance of the vaginal microbiome. This research emphasizes the importance of exploring plant-based antimicrobial agents as viable alternatives to traditional antibiotics. The significant antimicrobial properties of clove extract against common vaginal pathogens offer promising implications for future therapeutic applications in managing vaginal infections.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Omoniyi, A. T., Yaqub, M.. 2024-06-14. Antimicrobial Activity of Clove Extracts against Microorganisms Isolated from Vaginal Discharge. https://doi.org/10.1101/2024.06.13.598938

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

pTRIP, a novel integration plasmid for Listeria monocytogenes

In the past decades, several tools to genetically modify the human pathogen Listeria monocytogenes were developed. Here, we constructed a new integrative plasmid system for L. monocytogenes named pTRIP, for treB insertion plasmid. pTRIP is a vector which stably integrates into the treB locus of the wild type EGD-e. This locus encodes the sole trehalose-specific EIIB and EIIC component of a phosphotransferase system. Successful integration leads to the disruption of treB and thus, to an inability of the resulting L. monocytogenes strains to grow on trehalose as sole carbon source. Due to integration through double homologous recombination, it is the first integrative system which does not require antibiotic selection pressure. To assess functionality of the pTRIP system, prfA and its native promoter region were integrated into the treB locus of a {Delta}prfA strain. Complementation was confirmed in 78% of the isolated clones, indicating successful integration of prfA into the treB locus. We further constructed derivatives of pTRIP harboring the constitutive Pp60 (pTRIP1) and the inducible Prha (pTRIP2) promoter to further expand application possibilities. Microscopic analyses confirmed the functionality of both promoter constructs and showed dose-dependent induction for Prha. pTRIP is an efficient tool for stable gene expression as well as functional studies and expands genetic modification possibilities for L. monocytogenes.

microbiology↗

A rational design strategy and validation for protease-resistant fusion-inhibitor antiviral peptides

Peptide-based fusion inhibitors are promising pharmaceuticals in the fight against enveloped viruses relying on membrane fusion for host infection. However, peptide therapeutic applications have long been hindered by their poor stability in vivo. Here, we discovered that peptide inhibitors with the wildtype sequence of the heptad repeat 2 (HR2) domain of the SARS-CoV-2 spike protein are efficiently cleaved by Transmembrane Protease, Serine 2 (TMPRSS2), a key protease involved in the SARS-CoV-2 virus-cell fusion pathway. We then identified the corresponding cleavage sites and designed three protease-resistant peptides using ranking based on deep mutational scanning and natural occurrence. The three candidates all exhibit inhibitory activity in a cell-cell fusion assay. A high-resolution cryo-EM structure of the top candidate, HR2-NHN, bound to its HR1 target reveals the molecular basis for its potent activity. The top candidate of the cell-based screening assay significantly improved efficacy relative to the wildtype peptide when administered 12 h before infection in both an authentic virus-cell infection assay and a mouse assay. More broadly, our results suggest that the design strategies for protease-resistant peptides could be applied to a broad spectrum of other enveloped viruses and pave the way for the development of safe, prophylactic antivirals that can be administered before exposure.

microbiology↗

Host soluble inositol phosphate signaling promotes coronavirus replication

Coronaviruses rely extensively on host pathways for replication, making host-directed therapies an attractive strategy for broad-spectrum antivirals with reduced risk of viral resistance. Here we identify the host soluble inositol phosphate pathway as a previously unrecognized dependency for coronavirus infection. Genetic or pharmacologic inhibition of several kinases in this pathway markedly suppresses replication of both alpha- and betacoronaviruses, while increasing pathway activity promotes viral replication. We developed UNC7844, a potent multi-target inhibitor of these kinases, which reduces coronavirus replication by more than four orders of magnitude in cultured cells and suppresses coronavirus infection in mice. Mechanistically, UNC7844 suppresses inositol (pyro)phosphates production, disrupts phosphoinositide homeostasis, and impairs late endosomal dynamics, blocking early post-entry steps required for viral genome release and replication. Together, our findings establish the soluble inositol (pyro)phosphate pathway as an important regulator of coronavirus infection and highlight its inhibition as a promising host-directed antiviral strategy.

microbiology↗